DISCOUNT OPTIONSSCHEIN - MODERNA | Delayed Deutsche Boerse AG 10:53:39 2024-05-20 EDT | ||
| 1.28 EUR | -22.89% |
|
| Current month | -49.39% | ||
| 1 month | -54.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-20 | 1.28 | -22.89% |
| 24-05-17 | 1.66 | -6.21% |
| 24-05-16 | 1.77 | -14.49% |
| 24-05-15 | 2.07 | -5.48% |
| 24-05-14 | 2.19 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update May 20, 2024 at 07:52 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VU1FG1 |
| ISIN | DE000VU1FG13 |
| Date issued | 2023-01-03 |
| Strike | 150 $ |
| Maturity | 2024-06-21 (32 Days) |
| Parity | 10 : 1 |
| Emission price | 1.62 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.27 € |
|---|---|
| Lowest since issue | 1.48 € |
| Spread | 0.01 € |
| Spread % | 0.75% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
132.9
USD
Average target price
138.5
USD
Spread / Average Target
+4.22%
- Stock Market
- Certificates
- Certificat
